Abstract:BackgroundLittle is known about the long-term prognosis of patients with IgA nephropathy (IgAN).MethodsThis retrospective cohort analysis evaluated clinical and histological findings at the time of renal biopsy, initial treatment, patient outcomes over 30 years, and risk factors associated with progression in 1,012 patients diagnosed with IgAN at our center since 1974.ResultsOf the 1,012 patients, 40.5% were male. Mean patient age was 33±12 years and mean blood pressure was 122±17/75±13 mmHg. Mean serum creati… Show more
“…IgAN is not a benign disease; according to a retrospective cohort analysis evaluated clinical and histological findings in 1012 patients diagnosed with IgAN, with about 50% of patients progressing to ESRD within 30 years despite treatment, this study also shown that tonsillectomy plus steroids dramatically improved renal outcome. 17 Although the recent Kidney Disease:…”
Background The efficacy of tonsillectomy in immunoglobulin A nephropathy (IgAN) remains controversial. The aim of the study was to conduct a randomized controlled trial to evaluate the effect of tonsillectomy in patients with IgAN. Methods We randomly selected 98 patients with biopsy-proven IgA nephropathy and randomly allocated to receive tonsillectomy combined with drug therapy (Group A) or drug therapy alone (Group B). The participating patients were entered into a 4-year single-center study. Remission and relapse rate were calculated for hematuria and proteinuria using the Kaplan-Meier method. Results No differences were found between the two groups in their baseline clinical and histological characteristics. Patients with tonsillectomy exhibited considerable improvement in the following aspects compared to those patients who did not undergo tonsillectomy: time to reach first remission (3.1 vs. 24.9 months, p50.001) for hematuria and (2.5 vs. 26.1 months, p50.001) for proteinuria, cumulative remission rate (91.8% vs. 46.9%, p50.001 by log-rank test) for hematuria and (95.9% vs. 51.0%, p50.001) for proteinuria, the duration of first remission (26.5 vs. 11.8 months, p ¼ 0.0047) for hematuria and (23.5 vs. 10.5 months, p ¼ 0.0012) for proteinuria, as well as lower relapse rate for hematuria and proteinuria in Group A. Conclusion Our clinical data demonstrated that tonsillectomy could be beneficial for IgAN patients, particularly by contributing to faster and longer remission, as well as reducing the frequency of possible future relapses.
“…IgAN is not a benign disease; according to a retrospective cohort analysis evaluated clinical and histological findings in 1012 patients diagnosed with IgAN, with about 50% of patients progressing to ESRD within 30 years despite treatment, this study also shown that tonsillectomy plus steroids dramatically improved renal outcome. 17 Although the recent Kidney Disease:…”
Background The efficacy of tonsillectomy in immunoglobulin A nephropathy (IgAN) remains controversial. The aim of the study was to conduct a randomized controlled trial to evaluate the effect of tonsillectomy in patients with IgAN. Methods We randomly selected 98 patients with biopsy-proven IgA nephropathy and randomly allocated to receive tonsillectomy combined with drug therapy (Group A) or drug therapy alone (Group B). The participating patients were entered into a 4-year single-center study. Remission and relapse rate were calculated for hematuria and proteinuria using the Kaplan-Meier method. Results No differences were found between the two groups in their baseline clinical and histological characteristics. Patients with tonsillectomy exhibited considerable improvement in the following aspects compared to those patients who did not undergo tonsillectomy: time to reach first remission (3.1 vs. 24.9 months, p50.001) for hematuria and (2.5 vs. 26.1 months, p50.001) for proteinuria, cumulative remission rate (91.8% vs. 46.9%, p50.001 by log-rank test) for hematuria and (95.9% vs. 51.0%, p50.001) for proteinuria, the duration of first remission (26.5 vs. 11.8 months, p ¼ 0.0047) for hematuria and (23.5 vs. 10.5 months, p ¼ 0.0012) for proteinuria, as well as lower relapse rate for hematuria and proteinuria in Group A. Conclusion Our clinical data demonstrated that tonsillectomy could be beneficial for IgAN patients, particularly by contributing to faster and longer remission, as well as reducing the frequency of possible future relapses.
“…Proteinuria decreased by a median of 0.5 g/24h during follow-up. Overall, the median number of creatinine, proteinuria, and blood pressure measurements was 5 (3)(4)(5)(6)(7)(8), 4 (3-7), and 5 (3)(4)(5)(6)(7)(8), respectively.…”
Current guidelines suggest treatment with corticosteroids (CS) in IgA nephropathy (IgAN) when proteinuria is persistently $1 g/d despite 3-6 months of supportive care and when eGFR is .50 ml/min per 1.73 m 2 . Whether the benefits of this treatment extend to patients with an eGFR#50 ml/min per 1.73 m 2 , other levels of proteinuria, or different renal pathologic lesions remains unknown. We retrospectively studied 1147 patients with IgAN from the European Validation Study of the Oxford Classification of IgAN (VALIGA) cohort classified according to the Oxford-MEST classification and medication used, with details of duration but not dosing. Overall, 46% of patients received immunosuppression, of which 98% received CS. Treated individuals presented with greater clinical and pathologic risk factors of progression. They also received more antihypertensive medication, and a greater proportion received renin angiotensin system blockade (RASB) compared with individuals without immunosuppressive therapy. Immunosuppression was associated with a significant reduction in proteinuria, a slower rate of renal function decline, and greater renal survival. Using a propensity score, we matched 184 subjects who received CS and RASB to 184 patients with a similar risk profile of progression who received only RASB. Within this group, CS reduced proteinuria and the rate of renal function decline and increased renal survival. These benefits extended to those with an eGFR#50 ml/min per 1.73 m 2 , and the benefits increased proportionally with the level of proteinuria. Thus, CS reduced the risk of progression regardless of initial eGFR and in direct proportion to the extent of proteinuria in this cohort.
“…Sixteen such studies [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] , including cohorts from Europe, North America, and East Asia were meta-analysed in a report published in 2013 21 . Lately, more studies have been published including cohorts from Iran, Europe, Japan and Korea [22][23][24][25][26][27][28] . All these studies are summarised in Supplementary Table 1.…”
Section: Published Retrospective Validation Studiesmentioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.